Thanks for your comments @hargeo I’m at home today and am enjoying this debate. As you are aware there have been few bigger IMU bulls than myself during the past three years, even fewer people have been more supportive of management decisions, but sometimes you have to call a spade a spade. Any healthcare analyst worth their salt values Imugene’s IP at four to five times the current share price. Yet everyday shareholders have to sit and watch as pathetic bots control the daily share price movement and watch minuscule volumes go through, for no other reason than the Imugene Board and management have failed to entice anyone to buy large volumes of their shares. As you noted giving shares away at a discount to the current share price hasn’t helped. Many of us have introduced family and friends to a company with infinite intrinsic value, only to find them losing money on our watch. I too feel you pain…..
@Steini I’m well aware the products Imugene are developing are not akin to pain relief tablets. Neither with all due respect were the CTx products I wrote about in my post this morning. They were in fact cancer treatment products, which managed to find their way into commercial deals and partnerships with Merck and Pfizer for as their CEO Brett Carter noted potential returns of billions of dollars. You may be unaware but the majority of deals concluded in the biotech space are for drugs being developed, such as those within the Imugene stable. They are not necessarily sold, as you keep referring the transaction outcome to. In the majority of instances an upfront payment followed by milestone payments based upon future results are the way these deals are structured. In your example the suggestion of selling Her Vaxx or the entire platform at a discount may not be opportune. There are countless ways to construct a partnership arrangement, or skin a cat as it were. Just look at the Genentec/Roche deal many years ago, of which the Imugene CEO and Managing Director Leslie Chong is acutely aware. But it is hardly opportune to continue inviting third party pharmaceutical company’s into the Imugene house without so much as a hint of future commercialisation. In recent years Imugene has hopped into bed with Pfizer, Merck, Merck Germany, Roche, Celularity, Estrella and now Arovella, with no definitive revenue structure, profit orientation or business relationship shareholders are aware of. Imugene is not a research company, as the Board of Directors are soon to find out, it is a public company owned by its shareholders who require commercial transparency at all times.
@Steini for many IMU shareholders out licensing the Oncarlytics platform to the broad spectrum of Car T providers and allogenic therapy company’s who could benefit from the technology would be a step in the right direction. Bringing in ongoing revenue at a good margin without selling the house, (i.e., as you appear to think is the only outcome shareholders are searching for.) That way the company could build value for shareholders over time and in doing so avoid a takeover from a rampant hedge fund or pharmaceutical scavenger, a plight which is definitely on the cards at the ripe old stock price of 14 cents AUD. Or perhaps the Imugene management could strike territorial deals with pharmaceuticals or regional investors for their B cell vaccines in domiciles such as Korea, Japan or Singapore, where gastric and lung cancer are prevalent and patents exist. From where I sit that would add value to any future sale of their platform and at the same time provide the necessary funds to continue developing their drugs through to the Phase 3 stage you speak of, where maximum value could be obtained.
Don’t be under any illusion though, the average IMU shareholder who is holding long term and not abandoned ship is into Imugene for the huge value present within the company’s IP holding. But they are no longer prepared to sit back and wait and listen to the same old science rhetoric fed to them in newsletter after newsletter. The majority of registry entrants in recent years might just as well believe Imugene’s business management live under the misconception that Big Pharma came into the Imugene house to get out of the rain, as opposed to buying anything. If this is indeed true, the business management team may not be in a position to think that for much longer.VIDEO
DYOR - Opinions Only
(20min delay)